U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Clinical Review Report: Ocrelizumab (Ocrevus): (Hoffmann-La Roche Limited): Indication: Treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Dec.

Cover of Clinical Review Report: Ocrelizumab (Ocrevus)

Clinical Review Report: Ocrelizumab (Ocrevus): (Hoffmann-La Roche Limited): Indication: Treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features [Internet].

Show details

References

1.
Summary of clinical efficacy: section 2.7.3. Ocrelizumab BLA 761053 [CONFIDENTIAL internal manufacturer’s report]. San Francisco (CA): Genentech; [2016].
2.
Summary of clinical safety: section 2.7.4. Ocrelizumab BLA 761053 [CONFIDENTIAL internal manufacturer’s report]. San Francisco (CA): Genentech; [2016].
3.
Multiple sclerosis in adults: management [Internet]. London: National Institute for Health and Care Excellence; 2014 Oct 8. [cited 2017 Mar 13]. (Clinical guideline; no. 186). Available from: https://www​.nice.org​.uk/guidance/cg186/resources​/multiple-sclerosis-in-adults-management-35109816059077
4.
Olek MJ. Clinical course and classification of multiple sclerosis. In: Post TW, editor. UpToDate [Internet]. Waltham (MA): UpToDate; 2016 Oct [cited 2017 Feb 23]. Available from: www​.uptodate.com Subscription required.
5.
Helliwell CL, Coles AJ. Monoclonal antibodies in multiple sclerosis treatment: current and future steps. Ther Adv Neurol Disord [Internet]. 2009 Jul [cited 2017 Mar 13];2(4):195-203. Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles/PMC3002635 [PMC free article: PMC3002635] [PubMed: 21179528]
6.
Tsang BK, Macdonell R. Multiple sclerosis - diagnosis, management and prognosis. Aust Fam Physician. 2011 Dec;40(12):948-55. [PubMed: 22146321]
7.
Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014 Feb;89(2):225-40. [PubMed: 24485135]
8.
The burden of neurological diseases, disorders and injuries in Canada [Internet]. Ottawa: Canadian Institute for Health Information; 2007. [cited 2017 Mar 13]. Available from: https://secure​.cihi.ca​/free_products/BND_e.pdf
9.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol [Internet]. 2011 Feb [cited 2017 Mar 13];69(2):292-302. Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles/PMC3084507 [PMC free article: PMC3084507] [PubMed: 21387374]
10.
What is MS? [Internet]. Toronto: Multiple Sclerosis Society of Canada; 2017. [cited 2017 Mar 13]. Available from: https://mssociety​.ca/about-ms/what-is-ms
11.
Freedman MS, Selchen D, Arnold DL, Prat A, Banwell B, Yeung M, et al. Treatment optimization in MS: Canadian MS working group updated recommendations. Can J Neurol Sci. 2013 May;40(3):307-23. [PubMed: 23603165]
12.
e-CPS [Internet]. Ottawa: Canadian Pharmacists Association; 2017 [cited 2017 Mar 13]. Available from: https://www​.etherapeutics.ca Subscription required.
13.
Aubagio© (teriflunomide tablets): 14 mg [product monograph] [Internet]. Mississauga (ON): Sanofi Genzyme, a division of sanofi-aventis Canada Inc.; 2017 Jan 25. [cited 2017 Oct 13]. Available from: https://pdf​.hres.ca/dpd_pm/00038165.PDF
14.
Tecfidera© (dimethyl fumarate delayed-release capsules): 12 mg and 240 mg [product monograph] [Internet]. Mississauga (ON): Biogen Canada Inc.; 2017 Feb 17. [cited 2017 Mar 13]. Available from: https://pdf​.hres.ca/dpd_pm/00038163.PDF
15.
Comparative clinical and cost-effectiveness of drug therapies for relapsing-remitting multiple sclerosis [Internet]. Ottawa: CADTH; 2013 Oct. [cited 2017 Mar 13]. (CADTH therapeutic review; vol. 1, no. 2b). Available from: https://www​.cadth.ca​/media/pdf/TR0004_RRMS_ScienceReport_e​.pdf [PubMed: 24279002]
16.
Soelberg Sorensen P. Safety concerns and risk management of multiple sclerosis therapies. Acta Neurol Scand. 2016 Nov 27. Epub ahead of print.
17.
Ocrevus (ocrelizumab): 300 mg/10 mL (30 mg/mL) [product monograph]. Mississauga (ON): Hoffman-La Roche Limited; 2017 Aug 14.
18.
ZinbrytaT (daclizumab beta): 150 mg/mL solution for injection [product monograph]. Mississauga (ON): Biogen Canada Inc.; 2016 Dec 7.
19.
PlegridyT(peginterferon beta-1a): liquid for injection 125 æg [product monograph] [Internet]. Mississauga (ON): Biogen Canada Inc.; 2016 Jun 16. [cited 2017 Mar 13]. Available from: https://pdf​.hres.ca/dpd_pm/00035457.PDF
20.
Lemtrada© (alemtuzumab): 12 mg/1.2 mL [product monograph] [Internet]. Mississauga (ON): Genzyme Canada, a division of sanofi-aventis Canada Inc.; 2016 Feb 26. [cited 2017 Mar 13]. Available from: https://pdf​.hres.ca/dpd_pm/00033852.PDF
21.
Gilenya© (fingolimod (as fingolimod hydrochloride)): oral capsules, 0.5 fingolimod [product monograph] [Internet]. Dorval (QC): Novartis Pharmaceuticals Canada Inc.; 2016 Dec 16. [cited 2017 Mar 13]. Available from: https://pdf​.hres.ca/dpd_pm/00037481.PDF
22.
Copaxone© (glatiramer acetate injection): 20 mg / 1 mL and 40 mg / 1 mL pre-filled syringes for subcutaneous injection [product monograph] [Internet]. Toronto: Teva Canada Limited; 2017 Feb 17. [cited 2017 Mar 13]. Available from: https://pdf​.hres.ca/dpd_pm/00038162.PDF
23.
Avonex© (interferon beta-1a): liquid for injection [product monograph] [Internet]. Mississauga (ON): Biogen Canada Inc.; 2016 Jun 27. [cited 2017 Mar 13]. Available from: https://pdf​.hres.ca/dpd_pm/00035455.PDF
24.
Rebif© (interferon beta-1a): 8.8 æg/0.2 mL, 22 æg/0.5 mL and 44 æg/0.5 mL solution for injection; multidose 22 æg x 3 (66 æg/1.5 mL); multidose 44 æg x 3 (132 æg/1.5 mL) solution for injection in pre-fille catridge. Rebif© RebiDoseT 8.8 æg/0.2 mL, 22 æg/0.5 mL and 44 æg/0.5 mL solution for injection [product monograph] [Internet]. Mississauga (ON): EMD Serono; 2011 May 9. [cited 2017 Mar 13]. Available from: https://pdf​.hres.ca/dpd_pm/00013126.PDF
25.
Extavia© (interferon beta-1b): lyophilized powder for subcutaneous injection 0.3 mg/vial [product monograph] [Internet]. Dorval (QC): Novartis Pharmaceuticals Canada Inc; 2016 May 24. [cited 2017 Mar 13]. Available from: https://pdf​.hres.ca/dpd_pm/00036353.PDF
26.
Betaseron© (interferon beta-1b): lyophilized powder for subcutaneous injection 0.3 mg/vial [product monograph] [Internet]. Mississauga (ON): Bayer Inc.; 2016 Aug 15. [cited 2017 Mar 13]. Available from: https://pdf​.hres.ca/dpd_pm/00036140.PDF
27.
Tysabri© (natalizumab): concentrate for solution for intravenous infusion 300 mg/15 mL [product monograph] [Internet]. Mississauga (ON): Biogen Canada Inc.; 2016 Aug 31. [cited 2017 Mar 13]. Available from: https://pdf​.hres.ca/dpd_pm/00036917.PDF
28.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017 Jan 19;376(3):221-34. [PubMed: 28002679]
29.
Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Medical review(s). In: Ocrevus (ocrelizumab). Company: Genentech, Inc. Application no.: 761053. Approval date: 31/03/2017 [Internet]. Rockville (MD): FDA; 2017 Mar 28 [cited 2017 May 30]. (FDA drug approval package). Available from: https://www​.accessdata​.fda.gov/drugsatfda_docs​/nda/2017/761053Orig1s000TOC.cfm
30.
Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Statistical review(s). In: Ocrevus (ocrelizumab). Company: Genentech, Inc. Application no.: 761053. Approval date: 28/03/2017 [Internet]. Rockville (MD): FDA; 2017 Mar 28 [cited 2017 May 30]. (FDA drug approval package). Available from: https://www​.accessdata​.fda.gov/drugsatfda_docs​/nda/2017/761053Orig1s000TOC.cfm
31.
Primary clinical study report: WA21092. A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of ocrelizumab in comparison to interferon beta-1a (Rebif ✹) in patients with relapsing multiple sclerosis [CONFIDENTIAL internal manufacturer’s report]. Basel (CH): F. Hoffmann-La Roche Ltd; 2016 Mar. Report No.: 1062034
32.
Primary clinical study report: WA21093. A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of ocrelizumab in comparison to interferon beta-1a (Rebif ✹) in patients with relapsing multiple sclerosis [CONFIDENTIAL internal manufacturer’s report]. Basel (CH): F. Hoffmann-La Roche Ltd; 2016 Mar. Report No.: 1062035
33.
A study of ocrelizumab in comparison with interferon beta-1a (Rebif) in participants with relapsing multiple sclerosis. 2010 Nov 23 [cited 2017 Jun 14; updated 2016 Oct 10]. In: ClinicalTrials.gov. Bethesda (MD): U.S. National Library of Medicine; 2000 -. Available from: https:​//clinicaltrials​.gov/show/NCT01247324 NLM Identifier: NCT01247324.
34.
A study of ocrelizumab in comparison with interferon beta-1a (Rebif) in participants with relapsing multiple sclerosis. 2011 Aug 8 [cited 2017 Jun 14; updated 2016 Oct 25]. In: ClinicalTrials.gov. Bethesda (MD): U.S. National Library of Medicine; 2000 -. Available from: https:​//clinicaltrials​.gov/show/NCT01412333 NLM Identifier: NCT01412333.
35.
Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler. 1999 Aug;5(4):244-50. [PubMed: 10467383]
36.
Meyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol [Internet]. 2014 Mar 25 [cited 2017 Aug 14];14:58. Available from: https://www​.ncbi.nlm​.nih.gov/pmc/articles​/PMC3986942/pdf/1471-2377-14-58.pdf [PMC free article: PMC3986942] [PubMed: 24666846]
37.
Maruish M, Kosinski M, Bjorner JB, Gandek B, Turner-Bowker DM, Ware JE. User’s manual for the SF-36v2 health survey. 3rd edition. Lincoln (RI): Quality Metric Incorporated; 2011.
38.
Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med [Internet]. 2001 Jul;33(5):350-7. [PubMed: 11491194]
39.
Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. PharmacoEconomics. 1999 Feb;15(2):141-55. [PubMed: 10351188]
40.
Multiple endpoints in clinical trials: guidance for industry. Draft guidance [Internet]. Rockville (MD): Food and Drug Administration; 2017. [cited 2017 Aug 8]. Available from: https://www​.fda.gov/downloads​/Drugs/GuidanceComplianceRegulatoryInformation​/Guidances/UCM536750.pdf
41.
Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis [Internet]. London: European Medicines Agency; 2015 Mar 26. [cited 2017 Apr 3]. Available from: http://www​.ema.europa​.eu/docs/en_GB/document_library​/Scientific_guideline​/2015/03/WC500185161.pdf
42.
CDR submission: Ocrevus (ocrelizumab), 300 mg/10 mL (30 mg/mL) concentrate for infusion. Company: Hoffman-La Roche Limited [CONFIDENTIAL manufacturer’s submission]. Mississauga (ON): Hoffman-La Roche Limited; 2017 May 25.
43.
A study of ocrelizumab in participants with relapsing remitting multiple sclerosis (RRMS) who have had a suboptimal response to an adequate course of disease-modifying treatment (DMT). 2015 Dec 18 [cited 2017 Jun 14; updated 2017 Jun 2]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2000 -. Available from: https:​//clinicaltrials​.gov/show/NCT02637856 NLM Identifier: NCT02637856.
44.
A study of ocrelizumab in participants with relapsing remitting multiple sclerosis (RRMS) who have had a suboptimal response to an adequate course of disease-modifying treatment (DMT). 2016 Aug 5 [cited 2017 Jun 14; updated 2017 Jun 2]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2000 -. Available from: https:​//clinicaltrials​.gov/show/NCT02861014 NLM Identifier: NCT02861014.
45.
Wilson K, McCool R, Glanville J, Edwards M, Fleetwood K. Systematic review and network meta-analysis of treatment for relapsing-remitting multiple sclerosis. York (GB): York Health Economics Consortium; 2017.
46.
Disease-modifying therapies for relapsing-remitting and primary-progressive multiple sclerosis: effectiveness and value [Internet]. Boston (MA): Institute for clinical and economic review; 2017 Mar 6. [cited 2017 Aug 16]. Available from: https://icer-review​.org​/wp-content/uploads​/2016/08/CTAF_MS_Final_Report_030617​.pdf Prepared for California Technology Assessment Forum.
47.
Hoffman-La Roche Limited comments regarding the draft Ocrevus CDR review [CONFIDENTIAL additional manufacturer’s information]. Mississauga (ON): Hoffman-La Roche Limited; 2017 Aug 30.
48.
Chapuis B, Helg C, Maurice P, Aapro M, Jeannet M, Irle C, et al. Super intensive treatment followed by bone marrow autograft in cases of hematologic neoplasms and solid tumors. Schweiz Med Wochenschr. 1988 Mar 12;118(10):341-6. French. [PubMed: 2452479]
49.
Ashton DS, Beddell CR, Cooper DJ, Lines AC. Determination of carbohydrate heterogeneity in the humanised antibody CAMPATH 1H by liquid chromatography and matrix-assisted laser desorption ionisation mass spectrometry. Anal Chim Acta. 1995;306(1):43-8.
50.
Barkhof F. MR imaging in monitoring the treatment of MS: making good use of resources. Advances in MRI Contrast. 1996;4(2):46-53.
51.
Alemtuzumab. Gynakologische Praxis. 2006;30(1):171.
52.
Costelloe L, O’Rourke K, Kearney H, McGuigan C, Gribbin L, Duggan M, et al. The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical). J Neurol Neurosurg Psychiatry [Internet]. 2007 Aug [cited 2017 Feb 21];78(8):841-4. Available from: https://www​.ncbi.nlm​.nih.gov/pmc/articles​/PMC2117755/pdf/841.pdf [PMC free article: PMC2117755] [PubMed: 17332049]
53.
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Nov;29(9):625-55. [PubMed: 18193114]
54.
Nortvedt MW, Riise T, Maeland JG. Multiple sclerosis and lifestyle factors: the Hordaland Health Study. Neurol Sci. 2005 Dec;26(5):334-9. [PubMed: 16388368]
55.
Hobart J, Freeman J, Lamping D, Fitzpatrick R, Thompson A. The SF-36 in multiple sclerosis: why basic assumptions must be tested. J Neurol Neurosurg Psychiatry. 2001 Sep;71(3):363-70. Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles/PMC1737568 [PMC free article: PMC1737568] [PubMed: 11511712]
56.
Nortvedt MW, Riise T, Myhr KM, Nyland HI. Performance of the SF-36, SF-12, and RAND-36 summary scales in a multiple sclerosis population. Med Care. 2000 Oct;38(10):1022-8. [PubMed: 11021675]
57.
Rovira A, Auger C, Alonso J. Magnetic resonance monitoring of lesion evolution in multiple sclerosis. Ther Adv Neurol Disord [Internet]. 2013 Sep [cited 2017 Mar 14];6(5):298-310. Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles/PMC3755529 [PMC free article: PMC3755529] [PubMed: 23997815]
58.
Klawiter EC. Current and new directions in MRI in multiple sclerosis. Continuum (Minneap Minn) [Internet]. 2013 Aug [cited 2017 Mar 14];19(4 Multiple Sclerosis):1058-73. Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles/PMC4234130 [PMC free article: PMC4234130] [PubMed: 23917101]
59.
Schaffler N, Kopke S, Winkler L, Schippling S, Inglese M, Fischer K, et al. Accuracy of diagnostic tests in multiple sclerosis-a systematic review. Acta Neurol Scand. 2011 Sep;124(3):151-64. [PubMed: 21070192]
60.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012 Nov 24;380(9856):1829-39. [PubMed: 23122650]
61.
Sormani MP, Bruzzi P. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol [Internet]. 2013 Jul;12(7):669-76. [PubMed: 23743084]
62.
Sormani MP, Bonzano L, Roccatagliata L, De Stefano N. Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs. Mult Scler. 2011 May;17(5):630-3. [PubMed: 21177320]
63.
Sormani MP, Stubinski B, Cornelisse P, Rocak S, Li D, De Stefano N. Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis. Mult Scler. 2011 May;17(5):541-9. [PubMed: 21148262]
64.
Kappos L, Moeri D, Radue EW, Schoetzau A, Schweikert K, Barkhof F, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet. 1999 Mar 20;353(9157):964-9. [PubMed: 10459905]
Copyright © 2017 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK534381
Contents

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (5.2M)

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...